1 completed, 1 recruiting, 1 unknown. 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Unknown 1 |
Follow GS 101: new trials by email Literature Review of GS 101 trials Research Report on GS 101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection GS101 injection, U.S. commercial Dupixent®, CN commercial Dupixent® - Atopic Dermatitis (AD) | Phase 1 | Completed | Jiangsu Genscend Biopharmaceutical Co., Ltd | 294 | 2026-03-05 | 2026-10-15 |
| A Phase III Study of GS101 Injection to Dupixent® GS101 injection, DUPIXENT® - Atopic Dermatitis (AD) | Phase 3 | Recruiting | Jiangsu Genscend Biopharmaceutical Co., Ltd | 572 | 2026-01-29 | 2026-10-15 |
| Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG aganirsen - Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma | Phase 2 / Phase 3 | Unknown | Gene Signal SAS | 333 | 2017-01-01 | 2016-10-31 |
Dermatitis, Atopic (2) · Glaucoma, Neovascular (1)
Jiangsu Genscend Biopharmaceutical Co., Ltd (2) · Gene Signal SAS (1)
China (2)
2014 (1)